Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nimvec AM494
- Development stage
- Preclinical
- Lead developer
- Amarna Therapeutics
- Modality
- Gene Therapies, Stem Cell Therapies → Cell Therapies
01
Overview
Nimvec AM494 is an investigational gene-modified therapy being developed by Amarna Therapeutics for the treatment of multiple sclerosis (MS). It is based on the company's proprietary Nimvec platform, which utilizes a replication-deficient Simian Virus 40 (SV40) vector for gene delivery. The Nimvec platform is designed to be non-immunogenic in humans, potentially allowing for sustained therapeutic effect and the possibility of repeat administration without triggering a neutralizing immune response. AM494 is specifically engineered to restore immune tolerance to myelin antigens, thereby addressing the underlying autoimmune cause of MS and preventing neurodegeneration. The program is currently in the IND-enabling stage of development.
- Brand names
- Nimvec
02
Targets
MOG (Myelin oligodendrocyte glycoprotein)
Beyond the preview
Go deeper on Nimvec AM494.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nimvec AM494.